"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
Atromid-S Capsules (clofibrate capsules) is ethyl 2-(p-chlorophenoxy)-2-methyl-propionate, an antilipidemic agent.
Its molecular formula is C 12 H 15 O 3 Cl, molecular weight 242.7, and boiling point 148-150°C at 25 mm Hg. It is a stable, colorless to pale-yellow liquid with a faint odor and characteristic taste, soluble in common solvents but not in water. Each Atromid-S (clofibrate) Capsule contains 500 mg clofibrate for oral administration.
Atromid-S Capsules (clofibrate) contain the following inactive ingredients: D&C Red No. 28, D&C Red No. 30, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No. 28, FD&C Red No. 40, FD&C Yellow No. 6, gelatin.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Atromid-S Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.